Evidence map›Paper›PMID 31585536›Full record

ArticleJournal of translational medicine2019

The protective role of microRNA-21 against coxsackievirus B3 infection through targeting the MAP2K3/P38 MAPK signaling pathway.

Feng He, Zonghui Xiao, Hailan Yao, Sen Li, Miao Feng, Wei Wang, Zhewei Liu, Zhuo Liu, Jianxin Wu

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Evidence for a TMAO-HULC-miRNA regulatory axis in colorectal cancer cells.International journal of molecular and cellular medicine · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Ly6GResearch (Washington, D.C.) · 2024
    Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. MicroRNAs in cardiovascular diseases.Medical review (2021) · 2022
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Feng HeDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics-Peking University Teaching Hospital, YaBao Road 2, Beijing, 100020, China.
Zonghui XiaoDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Hailan YaoDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Sen LiDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Miao FengDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Wei WangDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Zhewei LiuDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China.
Zhuo LiuDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics, YaBao Road 2, Beijing, 100020, China. liuzhuozhuo2005@163.com.
Jianxin WuDepartment of Biochemistry & Immunology, Capital Institute of Pediatrics-Peking University Teaching Hospital, YaBao Road 2, Beijing, 100020, China. jianxinwu_2000@sina.com.
Capital Institute of Pediatrics · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe P38 mitogen-activated protein kinase (MAPK) pathway plays an essential role in CVB3-induced diseases. We previously demonstrated microRNA-21 has potential inhibitory effect on the MAP2K3 which locates upstream of P38 MAPK and was upregulated in mouse hearts upon CVB3 infection. However, the effect and underlying mechanism of miRNA-21 on CVB3 infection remain unclear.

methodsWe detected continuous changes of cellular miRNA-21 and P38 MAPK proteins expression profiling post CVB3 infection in vitro within 12 h. P38 MAPK signaling was inhibited by the specific inhibitor, small interfering RNA and miRNA-21 mimic in vitro, CVB3 replication, cell apoptosis rate and proliferation were detected. Viral load in the mice heart, cardiomyocyte apoptosis rate and histological of the heart were also detected in the mice model of viral myocarditis pretreated with miRNA-21-lentivirus.

resultsWe observed significant upregulation of miRNA-21 expression followed by suppression of the MAP2K3/P38 MAPK signaling in CVB3-infected Hela cells. The inactivation of the MAP2K3/P38 MAPK signaling by P38 MAPK specific inhibitor, small interfering RNA against MAP2K3, or miRNA-21 overexpression significantly inhibited viral progeny release from CVB3-infected cells. Mechanistically, when compared with control miRNA, miRNA-21 showed no effect on capsid protein VP1 expression and viral load within host cells, while significantly reversing CVB3-induced caspase-3 activation and cell apoptosis rate, further promoting proliferation of infected cells, which indicates the inhibitory effect of miRNA-21 on CVB3 progeny release. In the in vivo study, when compared with control miRNA, miRNA-21 pretreatment remarkably inactivated the MAP2K3/P38 MAPK signaling in mice and protected them against CVB3 infection as evidenced by significantly alleviated cell apoptosis rate, reduced viral titers, necrosis in the heart as well as by remarkably prolonged survival time.

conclusionsmiRNA-21 were reverse correlated with P38 MAPK activation post CVB3 infection, miRNA-21 overexpression significantly inhibited viral progeny release and decreased myocytes apoptosis rate in vitro and in vivo, suggesting that miRNA-21 may serve as a potential therapeutic agent against CVB3 infection through targeting the MAP2K3/P38 MAPK signaling.

Indexed as

MAP Kinase Signaling System3' Untranslated RegionsAnimalsBase SequenceCaspase 3Coxsackievirus InfectionsEnterovirusEnzyme ActivationHeLa CellsHost-Pathogen InteractionsHumansMaleMAP Kinase Kinase 3Mice, Inbred BALB CMicroRNAsp38 Mitogen-Activated Protein Kinases3' Untranslated RegionsCaspase 3MAP2K3 protein, humanMAP Kinase Kinase 3MicroRNAsMIRN21 microRNA, humanp38 Mitogen-Activated Protein KinasesCVB3miRNA-21P38 MAPKViral release

Identifiers

PMID31585536
PMCPMC6778380
OpenAlexW3003175435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.